Bullish analysis on biosimilars, cash flow, and MariTide obesity trial sparks AMGN surge
Bullish analysis on biosimilars, cash flow, and MariTide obesity trial sparks AMGN 5.8% surge
- AMGN rose ~5.8% to around $357 on June 11, 2026, significantly outperforming the healthcare sector.
- Yahoo Finance and analyst reports cited bullish notes highlighting undervalued biosimilars platform and strong cash flow potential.
- Renewed optimism around MariTide (maridebart cafraglutide) and Phase 3 MARITIME-SWITCH trial targeting GLP-1 switchers for monthly dosing.
- Recent coverage frames 2026 as a "springboard year" with growth from obesity, cardiometabolic, and oncology drugs offsetting patent pressures.
- Building on Q1 results showing 6% revenue growth and double-digit gains from 16 products; no single breaking announcement but positive narrative momentum.
- Analyst views (including RBC and others) emphasize pipeline diversification in high-potential obesity market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.